Cagrilintide at a Glance

• Cagrilintide is a long-acting acylated analogue of human amylin engineered for once-weekly administration. It is an investigational compound not an approved medicine, in any jurisdiction.
• Native amylin, islet amyloid polypeptide (IAPP) is co-secreted with insulin from pancreatic beta cells and acts as a satiation signal. It is a poor drug candidate in its own right because it aggregates into amyloid fibrils and cagrilintide’s design is largely a solution to that problem.
• It is a non-selective agonist across the calcitonin receptor family engaging the calcitonin receptor and the AMY1, AMY2 and AMY3 amylin receptor complexes formed when that receptor associates with receptor activity-modifying proteins.
• Its principal central target is the area postrema and the wider dorsal vagal complex, a circumventricular region where amylin receptor components are expressed and where satiation signals are integrated.
• Phase 2 monotherapy produced clinically meaningful weight reduction over 26 weeks, modestly exceeding an approved GLP-1 receptor agonist comparator. The combination with semaglutide, CagriSema was then taken into the REDEFINE phase 3 programme.
• REDEFINE 1 reported roughly 22.7% mean weight reduction at 68 weeks a large effect in absolute terms that nonetheless fell short of the figure the developer had signalled. Nausea, vomiting and constipation are the reported tolerability limitation across the programme, consistent with the class.

What Is Cagrilintide?

Cagrilintide is a synthetic, acylated, 32-residue amylin analogue catalogued in PubChem as cagrilintide, CID 171397054, with the molecular formula C₁₉₄H₃₁₂N₅₄O₅₉S₂ and a molecular mass of roughly 4.4 kDa. It is also known by the development codes AM833 and NN0174-0833.

Its medicinal chemistry is unusually well documented for a peptide in research circulation, because the discovery programme was published. Kruse and colleagues (2021, PMID 34288673) described the development of cagrilintide in Journal of Medicinal Chemistry, and three design decisions define the molecule.

The backbone was engineered away from amyloid formation. Human amylin is one of the most aggregation-prone peptides in human physiology; its fibrils are the islet amyloid deposits found in type 2 diabetes. Substitutions in the amyloidogenic mid-sequence region, a strategy pioneered in the earlier amylin analogue pramlintide, which borrowed proline residues from the non-aggregating rat sequence, stabilise the peptide in solution and make a pharmaceutical formulation feasible.

A fatty diacid side chain was attached for protraction. Acylation with a long-chain fatty diacid, via a linker, confers reversible binding to circulating albumin. This is the same protraction strategy used across the long-acting incretin analogues, and it converts a peptide with a half-life measured in minutes into one compatible with once-weekly dosing.

The disulphide bridge and amidated C-terminus were retained because both are required for amylin receptor activity. The molecule therefore contains a cyclic N-terminal region, and its analytical chemistry must establish correct disulphide pairing rather than simply correct mass. The result behaves pharmacologically like amylin but pharmacokinetically like a weekly biologic, and is conspicuously more complex than the short linear peptides typical of research catalogues.

How Does Cagrilintide Work?

Amylin and Islet Amyloid Polypeptide Biology

Amylin is a 37-residue peptide hormone co-secreted with insulin from pancreatic beta cells in an approximately 1:100 molar ratio. Its physiological roles, established across several decades, are slowing of gastric emptying suppression of postprandial glucagon secretion and promotion of satiation a coordinated set of effects that reduce the rate at which nutrients arrive in the circulation after a meal.

Its pathological role is separate and more familiar: human amylin self-assembles into islet amyloid and the fibrillisation process is cytotoxic to beta cells. That is the reason amylin itself never became a drug. The distinction matters for reading claims about cagrilintide, which is designed to reproduce the hormonal actions of amylin while eliminating the amyloidogenic behaviour. It is not an amyloid-related agent.

The Calcitonin and Amylin Receptor Complexes

Amylin pharmacology is a receptor-assembly problem rather than a single-receptor problem, and this is the part of the mechanism most often misdescribed.

There is no dedicated “amylin receptor” gene. Amylin signals through the calcitonin receptor (CTR) a class B G protein-coupled receptor, when it is heterodimerised with one of three receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3). The resulting complexes are designated AMY1 (CTR + RAMP1), AMY2 (CTR + RAMP2) and AMY3 (CTR + RAMP3) and each has a distinct pharmacological profile. The molecular composition and pharmacology of these receptors were set out in a foundational review by Hay and colleagues (PMID 15494035).

Cagrilintide is characterised as a non-selective agonist of calcitonin family receptors it activates CTR itself as well as the AMY complexes. That is a deliberate profile rather than a shortcoming, and it distinguishes the non-selective amylin analogues from the selective amylin agonists now also in development. The practical consequence for research design is that a receptor-level experiment must specify which complex is being interrogated because RAMP co-expression determines what the readout means: a CTR-transfected line without RAMP expression is not an amylin receptor assay.

Satiety Signalling in the Area Postrema

The central site of action is comparatively well localised, which is unusual for a metabolic peptide.

The area postrema is a circumventricular structure in the dorsal medulla that lacks a complete blood–brain barrier, giving circulating peptides direct access to neurons. It expresses calcitonin receptor and RAMP components, and it is the classical entry point for amylin’s satiation signal. Work has shown that amylin receptor components and the leptin receptor are co-expressed in single rat area postrema neurons (PMID 26750109), providing an anatomical basis for interaction between adiposity and meal-related signals.

More recent work has mapped this circuitry against cagrilintide specifically. A cross-species atlas of the dorsal vagal complex identified neural mediators of cagrilintide’s effects on energy balance (PMID 39868309), moving the account from receptor expression to identified cell populations.

The area postrema’s location also explains the tolerability profile. It is the chemoreceptor trigger zone, the structure that initiates nausea and vomiting. The anatomy that makes amylin analogues effective is the same anatomy that makes them emetic and this is not an incidental side effect but a consequence of the target.

The Dual Amylin and GLP-1 Rationale

The rationale for combining an amylin analogue with a GLP-1 receptor agonist is that the two act through partly non-overlapping mechanisms converging on the same behaviour. GLP-1 receptor agonism reduces energy intake largely through hypothalamic and hindbrain circuits and delays gastric emptying; amylin receptor agonism acts through the area postrema and dorsal vagal complex, with its own effects on gastric emptying and glucagon.

Rodent work reported that CagriSema drives weight loss by reducing energy intake while preserving energy expenditure (PMC12286864), relevant because the compensatory fall in energy expenditure that accompanies weight loss is a principal reason weight is regained. The pharmacokinetic rationale is equally practical: both components use albumin-binding acylation and both support once-weekly administration, making co-formulation feasible.

Research Evidence

Preclinical and Pharmacokinetic Work

Preclinical characterisation covered receptor pharmacology against selective and non-selective comparator agonists, and rodent energy-balance work of the kind described above, with doses reported in nanomoles or micrograms per kilogram in the named species, strictly as the cited studies report them for those models, not as recommendations and not translatable across species or routes.

Clinical pharmacology has been reasonably thorough for an investigational compound. A dedicated thorough QT study reported that cagrilintide was not associated with clinically relevant QTc prolongation in healthy participants (PMID 39279639), and a further study reported that renal or hepatic impairment did not affect the pharmacokinetics, safety or tolerability of subcutaneous cagrilintide (PMC13356073). Negative safety-pharmacology findings rarely attract attention but are part of an honest assessment of a programme.

Phase 2 Monotherapy

The monotherapy signal is the cleanest evidence that amylin receptor agonism alone reduces body weight in humans.

Lau and colleagues (2021) reported a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial of once-weekly cagrilintide in The Lancet (PMID 34798060). It enrolled 706 participants across 57 sites in 10 countries, adults with a body mass index of at least 27 kg/m² with hypertension or dyslipidaemia but without diabetes, and randomised them across five escalating once-weekly dose levels an approved GLP-1 receptor agonist comparator (liraglutide), and placebo, over 26 weeks.

At the highest dose level tested, mean body weight reduction was 10.8% against 9.0% for the active comparator (difference 1.8%, P = 0.03), and reductions across dose levels exceeded placebo by 3.0% to 7.8% (P < 0.001). Gastrointestinal adverse events, nausea, constipation, diarrhoea, occurred in 41% to 63% of cagrilintide participants versus 32% on placebo, at rates broadly comparable to the active comparator.

Two things are worth noting. The effect size is genuinely competitive with first-generation GLP-1 monotherapy, which is the finding that justified the phase 3 programme. And the trial was dose-finding so the top dose level was selected on the basis of that curve rather than established in advance.

CagriSema and the REDEFINE Programme

REDEFINE 1 is the pivotal obesity trial and the reason cagrilintide is widely discussed. It was a double-blind, placebo- and active-controlled phase 3 trial enrolling 3,417 adults with obesity, or overweight with weight-related comorbidity, and without type 2 diabetes over 68 weeks with arms for the CagriSema combination, each component alone, and placebo. It was published in The New England Journal of Medicine (PMID 41259764); registry records for the programme are searchable at ClinicalTrials.gov.

The reported results, at the top dose combination:

Where it fell short. In absolute terms 22.7% mean weight reduction over 68 weeks is among the largest effects reported for a pharmacological obesity intervention. But the developer had publicly signalled an expectation in the region of 25% and the readout came in below that, a gap widely remarked upon at the time. The lesson for anyone reading the pharmacology is narrow: the trial did not fail; a forecast did. That distinction matters, because “CagriSema disappointed” is now a shorthand that misdescribes what was measured.

Two features of the design deserve attention. Because REDEFINE 1 included monotherapy arms for each component it is one of the few phase 3 obesity trials able to speak to the incremental contribution of the amylin component rather than only to the combination. And the estimand gap 22.7% versus 20.4% depending on whether the analysis conditions on adherence, is a reminder that a headline percentage from this class of trial always requires the analysis convention alongside it.

REDEFINE 2 extended the programme to adults with obesity or overweight and type 2 diabetes reporting mean weight reduction of approximately 16%. A smaller effect in diabetes is the consistent pattern across this therapeutic class rather than a compound-specific finding. A 2026 systematic review and GRADE-assessed meta-analysis of CagriSema trials (PMID 42608559) now provides a pooled synthesis, and a 2023 review of cagrilintide as a long-acting amylin analogue (PMID 36883831) covers the pre-REDEFINE dossier.

Gastrointestinal Tolerability as the Class Constraint

Across every trial in the programme, nausea, vomiting and constipation are the dominant adverse events at rates several-fold above placebo. This is mechanistically expected, the area postrema is both the satiation relay and the emetic trigger zone, and is reported as mostly transient and mild-to-moderate, with discontinuation for adverse events in single figures.

The research-relevant question is whether nausea and weight loss are separable. If satiation and emesis are mediated by overlapping area postrema populations, a tolerability-improved amylin agonist may necessarily be a less effective one. The dorsal vagal complex cell-atlas work addresses this question directly, and it is currently the most interesting open problem in amylin pharmacology.

What Remains Unknown

Regulatory outcome. Cagrilintide is investigational. No regulator has approved it, alone or in combination, and no approval should be assumed from trial results.

Durability and regain. The longest reported exposures run to 68 weeks. Whether the preserved energy expenditure seen in rodents translates into reduced regain after discontinuation in humans is untested.

Body composition. Reported outcomes are dominated by total body weight. Lean-mass preservation across a 20%-plus reduction is a substantive question this readout does not answer.

The incremental value of the amylin component over a maximally dosed GLP-1 receptor agonist alone, across long time horizons and in unselected populations, remains an open comparative question.

Comparison: Cagrilintide, Retatrutide and Tesamorelin

Metabolic research catalogues list these three side by side, and they are useful to compare precisely because they are mechanistically unrelated. Cagrilintide is a single-family peptide hormone analogue; retatrutide is a multi-receptor incretin agonist; tesamorelin acts on a different axis entirely.

Retatrutide is the nearest comparator in terms of research interest, and it takes the opposite engineering approach. Rather than combining two molecules, it is a single peptide agonising three receptors, GIP, GLP-1 and glucagon. Jastreboff and colleagues (2023, PMID 37366315) reported the phase 2 obesity trial in The New England Journal of Medicine. Catalogues list retatrutide as a separate research compound. The structural contrast is the point: cagrilintide adds a new hormone axis to incretin pharmacology, where retatrutide adds more receptors within incretin pharmacology. The dual-agonist incretin compounds already in clinical use, of which tirzepatide is the familiar example, sit between those strategies as a class reference.

Tesamorelin belongs to a different conversation and is included to make that clear. Catalogues list tesamorelin, a GHRH analogue acting on the pituitary to raise endogenous growth hormone secretion, with visceral adipose tissue rather than total body weight as its characteristic readout. It shares no receptor, no site of action and no outcome measure with the amylin or incretin compounds, and grouping the three as “weight loss peptides” obscures more than it explains.

Handling and Reconstitution of Lyophilised Cagrilintide

Cagrilintide is materially harder to handle than the short linear peptides common in research work, for three specific reasons.

It contains a disulphide bridge required for receptor activity and vulnerable both to reduction by any thiol-containing reagent, dithiothreitol, 2-mercaptoethanol, free cysteine in media, and to scrambling at alkaline pH. Near-neutral pH and the absence of reducing agents are not optional refinements; they determine whether the material in the vial is the active molecule.

It is acylated with a lipophilic side chain. The fatty diacid moiety confers surfactant-like behaviour: the molecule concentrates at air–liquid and liquid–solid interfaces, adsorbs to hydrophobic plastics, and can self-associate into micellar species at higher concentrations. Foaming genuinely damages the preparation, low-binding polypropylene is preferable to standard tubes, and apparent concentration can drift downward on storage through adsorption rather than degradation.

It is designed to bind albumin. In any buffer containing serum or bovine serum albumin, a large fraction of the peptide is protein-bound and free concentration is not nominal concentration. Cell-based work must state and control the albumin content of the medium or the effective exposure is unknown.

Standard reconstitution practice applies: equilibrate the vial to room temperature before opening, disinfect the septum with 70% isopropyl alcohol and let it dry, introduce the diluent slowly down the inner wall of the vial rather than onto the cake, and swirl or roll gently, never shake which for an acylated peptide is the single most consequential handling instruction.

Where a vial will be entered more than once, a monographed bacteriostatic water, listed beside the research compounds themselves at NextGenPeps, is the conventional laboratory choice, and Bacteriostatic Water for Injection, USP is what most protocols specify. Two caveats belong in the record. Benzyl alcohol is not inert toward peptides the formulation literature documents preservative-promoted unfolding and aggregation, and for an acylated, disulphide-containing peptide that concern is more than theoretical, so single-entry analytical preparations are better served by unpreserved sterile water. And it is contraindicated in neonatal use because of benzyl alcohol toxicity.

Store reconstituted solution at 2–8 °C, aliquot at the point of reconstitution rather than freeze–thawing repeatedly, buffer near neutral pH, and log the diluent lot alongside the peptide lot.

Is Cagrilintide FDA Approved?

No. Cagrilintide is an investigational compound. It has no marketing authorisation from the FDA, the EMA, the MHRA or any comparable authority, alone or in combination with semaglutide, for any indication, in any species.

This requires emphasis because the phase 3 results are large and widely reported, and large published results are routinely mistaken for approval. A completed phase 3 trial with a positive primary endpoint is a regulatory submission not a regulatory decision.

Cagrilintide is likewise not a lawful dietary supplement ingredient in the United States. A synthetic, acylated 32-residue peptide is not a dietary ingredient, and marketing it for human consumption places it outside both the drug and the supplement frameworks. Unlike several older research peptides, cagrilintide does not appear on the FDA’s list of certain bulk drug substances for use in compounding that may present significant safety risks, but absence from that list is not permission, and an investigational compound under active development by its originator is not available for lawful human use outside a clinical trial.

The practical consequence is the ordinary one. Material sold for laboratory work is research-use-only no regulatory body has assessed the identity, purity or safety of any research-grade lot, and supplier documentation carries the entire evidentiary burden.

Where to Buy Research-Grade Cagrilintide

Cagrilintide is one of the harder molecules in the research catalogue to make correctly. A 32-residue peptide with an intramolecular disulphide, a C-terminal amide and a fatty diacid conjugation is a multi-step synthesis with several distinct failure modes, and the failures are not all visible on a coarse chromatogram. A defensible purchase record contains:

• A lot-matched certificate of analysis tied to the specific lot shipped rather than to a representative batch.
• Third-party HPLC purity data with a named laboratory, a stated method and a test date. The impurities that matter here are deletion and truncated sequences unconjugated or partially conjugated peptide where the acylation step was incomplete, disulphide isomers and reduced open-chain material and deamidated species. A flat trace with a stated percentage tells you none of this.
• Mass spectrometry consistent with the expected ~4.4 kDa acylated species which is the practical check on whether the fatty diacid side chain is present. Note that MS alone cannot distinguish disulphide isomers which are isobaric.
• Explicit confirmation of disulphide formation by a method that addresses it, peptide mapping, reduction-shift comparison, or a stated oxidation and folding step in the synthesis record. This is the most commonly missing item in documentation for cyclic peptides.
• Declared net peptide content distinct from gross vial fill weight, and residual trifluoroacetate data where available, since TFA contributes mass and is cytotoxic at low concentrations in cell work.
• Cold-chain shipping and cold, dry storage with explicit research-use-only labelling and no suggested protocol, dosing guidance or human-use framing anywhere in the listing.

Red flags here are predominantly editorial. A listing that presents REDEFINE results as though the compound were approved, or describes it as a treatment rather than an investigational molecule, has misstated its regulatory status. Listings quoting human milligram regimens, titration schedules or injection guidance are a compliance signal about the supplier independent of product quality. And purity claims of “99%+” with no chromatogram, named method or test date are not data, least of all for a molecule where the most important quality attribute, correct disulphide pairing, does not appear in a purity percentage at all.

A catalogue that lists cagrilintide as a research compound can be assessed against exactly these criteria, in that order: lot-matched third-party HPLC with a resolved chromatogram; mass spectrometry consistent with the acylated species; documented disulphide confirmation; declared net peptide content; residual solvent figures; documented cold chain; and research-use-only labelling with no protocol content attached. For this molecule the disulphide question should be treated as disqualifying if it cannot be answered.

Frequently Asked Questions

What is the difference between amylin, pramlintide and cagrilintide?

Amylin is the native 37-residue human hormone, co-secreted with insulin; it aggregates into amyloid and is not viable as a drug. Pramlintide is a short-acting analogue with proline substitutions borrowed from the non-aggregating rat sequence, requiring multiple daily injections. Cagrilintide is a long-acting acylated analogue engineered for once-weekly administration, with albumin binding conferred by a fatty diacid side chain.

What are AMY1, AMY2 and AMY3 receptors?

They are not separate genes. Each is a heterodimer of the calcitonin receptor with one of three receptor activity-modifying proteins RAMP1, RAMP2 or RAMP3 respectively. RAMP association changes the receptor’s pharmacology, converting a calcitonin receptor into an amylin-preferring one. Cagrilintide is non-selective across this family, also activating the calcitonin receptor itself.

Why does cagrilintide cause nausea?

Because its principal site of action, the area postrema is also the chemoreceptor trigger zone that initiates nausea and vomiting. The anatomy that delivers the satiation signal is the anatomy that delivers the emetic signal. Whether the two can be pharmacologically separated is an open research question and the most interesting one in the field.

Did CagriSema fail in REDEFINE 1?

No. REDEFINE 1 reported roughly 22.7% mean weight reduction at 68 weeks against about 2.3% on placebo, among the largest effects reported for any pharmacological obesity intervention. What fell short was the developer’s publicly signalled expectation of around 25%. The trial met its endpoint; a forecast did not. Conflating the two is the most common error in secondary coverage.

Is cagrilintide approved anywhere?

No. It is investigational in every jurisdiction, alone and in combination. Published phase 3 results constitute a regulatory submission, not a regulatory decision, and no approval should be inferred from them.

Why is the disulphide bond such a handling concern?

Because it is required for receptor activity and is chemically fragile. Reduction by any thiol-containing reagent, or scrambling at alkaline pH, produces material with the same nominal mass but different, usually absent, activity. Mass spectrometry cannot distinguish the isomers, so the disulphide has to be confirmed by a method that addresses it specifically.

The Bottom Line

Cagrilintide is one of the most substantively evidenced compounds in the research-peptide catalogue, and also one of the most frequently misdescribed.

What is well supported: it is a well-characterised, published molecule with a documented discovery programme, a defined receptor pharmacology across the calcitonin receptor family, and a localised central site of action in the area postrema and dorsal vagal complex. Monotherapy reduces body weight in humans the phase 2 trial in 706 participants established that amylin receptor agonism alone produces effects competitive with first-generation GLP-1 monotherapy. The combination with semaglutide produces very large weight reductions: REDEFINE 1 reported roughly 22.7% at 68 weeks in 3,417 participants, with 40.4% reaching a 25% reduction.

What is not supported: any claim of approval since the compound is investigational everywhere. Any claim that the gastrointestinal burden is minor nausea at 55% and vomiting at 26% against placebo rates of 12.6% and 4.1% is the defining practical constraint of the class, and it is mechanistically tied to the target rather than incidental. Durability beyond the trial horizon which is untested. And body composition outcomes which the published weight endpoints do not address.

For a laboratory, the compound is a legitimate tool for amylin receptor pharmacology, with the proviso that it is technically demanding material: the disulphide and the acyl chain make synthesis and handling genuinely harder than for the short peptides that dominate this market, and documentation that does not address the disulphide has not established what is in the vial.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

Cagrilintide, retatrutide, tesamorelin and all other compounds discussed in this article are intended for laboratory research use only. Cagrilintide is an investigational compound and is not approved by the U.S. Food and Drug Administration, the European Medicines Agency or any comparable authority for the diagnosis, treatment, cure or prevention of any disease, in any species, alone or in combination. It is not an approved dietary supplement ingredient. Published clinical trial results do not constitute approval.

Nothing in this article is medical, veterinary or pharmaceutical advice, and nothing in it constitutes a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind. Peptides described here are not for human or veterinary use. Dose levels referred to from clinical trials are protocol parameters of studies conducted under medical supervision, and doses quoted from animal work are reported in the terms the original investigators used for the specific model studied; none are recommendations or equivalents for any other species, route or context. Reported weight-change and adverse-event figures are summaries of what the cited literature reports, not endorsements or claims of efficacy or safety. Readers with clinical questions about obesity or diabetes should consult a qualified healthcare professional. Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules in their jurisdiction.

Stay updated, free articles. Join our Telegram channel

Join